WO2002060446A1 - Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient - Google Patents
Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient Download PDFInfo
- Publication number
- WO2002060446A1 WO2002060446A1 PCT/JP2002/000544 JP0200544W WO02060446A1 WO 2002060446 A1 WO2002060446 A1 WO 2002060446A1 JP 0200544 W JP0200544 W JP 0200544W WO 02060446 A1 WO02060446 A1 WO 02060446A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- tablet
- group
- tablet according
- hydroxypropylcellulose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
Definitions
- the present invention relates to a tablet containing 5-methyl-1-phenyl-2- (1H) -pyridone as a main drug.
- 5-Methyl-1-phenyl-2- (1H) -pyridone is a drug targeted at pulmonary fibrosis.
- pirfenidone is a drug targeted at pulmonary fibrosis.
- Various effects have been reported to date on pirfenidone.
- 1) Japanese Patent Application Laid-Open No. 2-215157 / 19 shows that it has a therapeutic effect on fibrosis in the lungs and atherosclerotic lesions
- Inhibiting the synthesis and release of TNF- ⁇ is described in Japanese Patent Application Laid-Open No. 11-512699.
- the dosage forms of pirfenidone include capsules, tablets, powders, granules, syrups, injections, creams, ointments, inhalants, eye drops, suppositories, and 1) and 2) above.
- pills are exemplified, the preferred dosage forms are capsules, injections, creams, and ointments, and the examples only describe capsules and ointments. That is, there is no specific description of the method for producing the tablet of pirfenidone.
- capsules there are eight types of capsules, ie, 00, 00, 0, 1, 2, 3, 4, and 5, and the larger the number, the smaller the size.
- effects such as bulk density and compressibility of the drug to be filled, but in general, 60 mg or more for No. 5 capsules: L 0 O mg, and 100 mg to 170 mg for No. 4 capsules: 140 mg to 220 mg for the No. 3 capsule: about 18 mg to 300 mg for the No. 2 capsule, 240 mg to 390 mg for the No. 1 capsule, and about 3400 mg to 540 mg for the No. 0 capsule Can be charged.
- capsules to be administered to humans capsules Nos.
- the drug to be filled into the capsule is not usually the active ingredient alone, but is formulated with excipients, binders, disintegrants, etc. in order to improve the stability and efficacy of the active ingredient. Is used.
- the formulated pirfenidone granules or mixed powder filled in the capsule is about 80%. It becomes 0 mg-850 mg.
- the dose is higher, it is practically difficult to obtain a practical capsule. Disclosure of the invention
- tablets for oral administration are easier to take than capsules.
- the present inventors have studied the formulation into tablets that are considered to be useful for improving compliance when a large amount of pirfenidone is orally administered.
- the present inventors have conducted intensive studies, and as a result, smell and bitterness are masked, light stability is improved, fast dissolution rate and stability are ensured, and the content of the main drug is increased. Nevertheless, they have found a pirfenidone tablet that is compact, has sufficient hardness, and has improved compliance, and has completed the present invention. That is, the present invention
- Lactose 10 to 50% by weight, lactose, 5 to 40% by weight, carme sucrose, 1 to 10% by weight, hydroxypropyl cellulose, and 0.5 to 5% by weight, respectively, based on the active ingredient % Of magnesium stearate and 2-6% by weight, based on the active substance, of hydroxypropylmethylcellulose, 0.01-1% by weight of triethyl citrate, and 0.05%.
- a plasticizer selected from the group consisting of a coating base, triethyl citrate, and triacetin, and 0.8 to 3% by weight of titanium oxide as a light shielding agent
- a plasticizer selected from the group consisting of a coating base, triethyl citrate, and triacetin, and 0.8 to 3% by weight of titanium oxide as a light shielding agent
- light acids such as light anhydrous silicic acid, synthetic aluminum silicate, and magnesium aluminate metasilicate, inorganic salts such as calcium phosphate, calcium carbonate, calcium sulfate, lactose, sucrose, glucose, mannite, sorbite, etc.
- inorganic salts such as calcium phosphate, calcium carbonate, calcium sulfate, lactose, sucrose, glucose, mannite, sorbite, etc.
- lactose corn starch, crystalline cellulose and the like.
- the term “disintegrant” means an additive used for the purpose of disintegrating and dispersing the preparation into fine particles by infiltrating in the digestive tract when taking a tablet.
- examples include corn starch, carboxymethylcellulose, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, carmellose sodium, croscarmellose sodium, carboxymethyl starch sodium, cross-linked polyvinyl pyrrolidone, and the like.
- carmellose skull Shim low-substituted hydroxypropylcellulose, cross-linked polyvinylpyrrolidone, and the like.
- the term “binder” refers to a binder used in ordinary preparation of a pharmaceutical preparation. For example, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone and the like can be mentioned. Particularly preferred are hydroxypropylcellulose, polyvinylpyrrolidone and the like.
- examples of the “lubricant” include talc, calcium stearate, sodium stearate, magnesium stearate and the like. Particularly preferred are magnesium stearate, talc and the like.
- coating base includes sucrose, talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetate argetyl aminoacetate.
- Tate aminoalkyl methacrylate copolymer, cellulose acetate phthalate, methacrylic acid copolymer L, methacrylic acid copolymer LD, methyl acrylic acid copolymer S, hydroxypropylmethyl cell mouthpiece, hydroxymethyl
- examples include propylmethylcellulose acetate succinate, carboxymethylethylcellulose and the like. Particularly preferred are hydroxypropylmethylcellulose, hydroxypropylcellulose and the like.
- sunscreen agent means a sunscreen agent used in usual production of a pharmaceutical preparation.
- titanium oxide, iron dioxide, etc. are exemplified. Particularly preferred are titanium oxide and the like.
- plasticizer refers to a plasticizer used in ordinary preparation of a pharmaceutical preparation.
- plasticizer for example, triethyl citrate, triacetin, glycerin fatty acid esters, phthalic acid esters and the like are exemplified. Particularly preferred are triethyl citrate, triacetin and the like.
- the tablet of the present invention can be produced, for example, according to the following steps A) to D).
- a mixed powder containing pirfenidone, an excipient, and a disintegrant is prepared and granulated by using a commonly used fluidized bed granulator while spraying a binder to obtain granules.
- a disintegrant, a lubricant and the like are added to the obtained granules and mixed, and the mixture is tableted at 8 to 18 kN, preferably 11 to 15 kN, to obtain a pirfenidone plain tablet.
- the present invention relates to a tablet characterized by containing 5-methyl-1-phenyl-2- (1H) -pyridone as a main drug, and in particular, a tablet having a weight of 100 to 100. Those which are 100 mg are preferred. More preferably, it is 150 to 700 mg, most preferably 240 to 48 Omg. It is preferable that the tablet contains 10 to 85% by weight of the active ingredient with respect to the weight of the tablet. More preferably, it is 25 to 85% by weight, most preferably 50 to 85% by weight. It is preferable that the content of the main drug is from 200 mg to 400 mg.
- Tablets designed in this way are more compact, more chewy than capsules, and have a higher content of the main drug, so they can exert their efficacy effectively.
- the tablets of the present invention also include tablets that are more compact than capsules containing 5-methyl-1-phenyl-12- (1H) -pyridone as the main drug.
- the present inventor has found for the first time that there is a problem with the light stability in producing a tablet of pirfenidone, and by adding a light-blocking agent, a tablet of pirfenidone with improved light stability is obtained. I found it. Furthermore, it has been found that a tablet containing 0.05 to 3% by weight of a light-blocking agent with respect to the main drug is preferable, and a tablet containing a light-blocking agent in a coating layer is preferable.
- the tablet of the present invention also includes a tablet containing 5-methyl-11-phenyl-2- (1H) -pyridone as a main ingredient and having improved photostability.
- the preferred distribution amount of each component other than the active ingredient in the uncoated tablet is indicated by% by weight relative to the active ingredient pilfenidone.
- pirfenidone as the main drug is in a large amount, it is preferable to add other components in a range as small as possible, taking into consideration the taste of taking the drug.
- the tablet hardness may decrease.
- the excipient is preferably a) 10 to 50% by weight.
- b) is 15 to 40% by weight, and most preferably, c) is 20 to 30% by weight.
- the disintegrant is preferably d) 5 to 40% by weight. More preferably, e) is 5 to 25% by weight, and most preferably, f) is 7.5 to 15% by weight.
- the amount of the binder is preferably g) 1 to 10% by weight. More preferably, h) is 1 to 7.5% by weight, and most preferably, i) is 2 to 5% by weight.
- Lubricants are preferably j) 0.5-5% by weight. More preferably, k) is 0.5 to 4% by weight, most preferably 1) 0.5 to 3% by weight.
- the preferred distribution amount of each component in the coating liquid is shown in terms of% by weight based on the drug, pyrazine. Includes a coating base to mask the peculiar smell and bitterness of pirfenidone, and a light-blocking agent to improve photostability, but as in the case of plain tablets, each component is added in the smallest possible range It is preferable.
- the coating base is preferably m) 2 to 6% by weight. More preferably n) 2-5% by weight, most preferably. ) 2 to 4% by weight.
- the light-shielding agent is preferably p) 0.05 to 3% by weight. More preferably q) 0.05 to 2% by weight, most preferably r) 0.8 to 1.0% by weight. 5% by weight.
- the plasticizer is s) not included or, if present, t) 0.05 to 1% by weight.
- the tablet of the present invention exhibits excellent light stability as described in the experimental examples described below. In addition, despite the large amount of the main drug, it is a compact, chewy tablet with sufficient hardness.
- the dosage will vary depending on the condition of the disease, the route of administration, the age of the patient, or the weight of the patient. When administered to an adult, a dosage of about 1200 mg to about 180 mg per day will be preferred. Since this is a three-time-dose formulation, the dose per dose is between 4 mg and 600 mg, and it is preferable to take two tablets with a drug content of 200 mg to 300 mg. Good.
- the present invention will be described in more detail with reference to Examples and Test Examples, but the present invention is not limited thereto.
- pirfenidone To 2,000 g of pirfenidone, 560 g of lactose and 50 g of carmellose calcium were added to prepare a mixed powder, which was charged into a fluid bed granulator and sprayed with a 5% by weight aqueous solution containing 60 g of hydroxypropylcellulose. The resulting mixture was subjected to fluidized bed granulation to obtain granules. To the obtained granules, 5.6% by weight of carmellose calcium and 1.1% by weight of magnesium stearate were added, mixed and compressed (13 kN) to make a tablet of unmodified pirfenidone (12.0 X 6.0 mm, 285 mg / tablet containing 200 mg of pirfenidone per tablet).
- a 10% by weight aqueous coating solution containing 66.7 g of hydroxypropylmethylcellulose, 6.7 g of triethyl citrate and 26.6 g of titanium oxide was coated at 10 mg / tablet on the above-mentioned pirfenidone tablets using a high coater. Thus, the desired pilfenidone tablet was obtained.
- composition per tablet is as follows.
- Light irradiation apparatus Light stability test device (LTL400- D 5) (Nagano Science Kikai Seisakusho) Fluorescent: D65 fluorescent lamp for color comparison and inspection
- Color difference measurement device Color analyzer TC-1800MK-II
- Measurement method Reflected light measurement
- pirfenidone drug substance did not show any noticeable color change in powder state, but there was a problem with photostability in the case of pirfenidone compression molded products and pirfenidone breakdown.
- the use of pilfenidone tablets solved the problem of photostability.
- pirfenidone tablets had no problem in smell and bitterness.
- the present invention makes it easy to take pirfenidone, which requires a large amount of medication, into a tablet that is compact and has sufficient hardness despite having a large amount of the active ingredient, and at the same time solves the problem of odor and bitterness could be something.
- the problem of photostability caused by tableting pilfenidone was solved, and the stability required for pharmaceuticals was obtained.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/470,334 US7867516B2 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
JP2002560638A JP4077320B2 (ja) | 2001-01-29 | 2002-01-25 | 5−メチル−1−フェニル−2−(1h)−ピリドンを有効成分として含有する医薬製剤 |
DE60234812T DE60234812D1 (de) | 2001-01-29 | 2002-01-25 | Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält |
KR1020037009856A KR100777169B1 (ko) | 2001-01-29 | 2002-01-25 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
EP02710352A EP1356816B1 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
AT02710352T ATE452637T1 (de) | 2001-01-29 | 2002-01-25 | Arzneipräparat, das als wirkstoff 5-methyl-1- phenyl-2-(1h)-pyridon enthält |
US12/941,994 US20110104276A1 (en) | 2001-01-29 | 2010-11-08 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/333,142 US20120183615A1 (en) | 2001-01-29 | 2011-12-21 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
US13/662,221 US9017722B2 (en) | 2001-01-29 | 2012-10-26 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US14/671,251 US20150209341A1 (en) | 2001-01-29 | 2015-03-27 | Pharmaceutical composition containing as an active ingredient 5-methyl -1-phenyl-2-(1h)-pyridone |
US14/951,313 US9561217B2 (en) | 2001-01-29 | 2015-11-24 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone |
US15/385,451 US20170100380A1 (en) | 2001-01-29 | 2016-12-20 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-19393 | 2001-01-29 | ||
JP2001019393 | 2001-01-29 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10470334 A-371-Of-International | 2002-01-25 | ||
US10/470,334 A-371-Of-International US7867516B2 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US12/941,994 Continuation US20110104276A1 (en) | 2001-01-29 | 2010-11-08 | Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1h)-pyridone |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002060446A1 true WO2002060446A1 (en) | 2002-08-08 |
Family
ID=18885277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/000544 WO2002060446A1 (en) | 2001-01-29 | 2002-01-25 | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
Country Status (8)
Country | Link |
---|---|
US (7) | US7867516B2 (ja) |
EP (1) | EP1356816B1 (ja) |
JP (1) | JP4077320B2 (ja) |
KR (2) | KR100891887B1 (ja) |
AT (1) | ATE452637T1 (ja) |
DE (1) | DE60234812D1 (ja) |
TW (1) | TWI314868B (ja) |
WO (1) | WO2002060446A1 (ja) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005187339A (ja) * | 2003-12-24 | 2005-07-14 | Iwaki Seiyaku Co Ltd | 耐光性塩酸テルビナフィンフィルムコート錠 |
WO2010058844A1 (ja) | 2008-11-21 | 2010-05-27 | リードケミカル株式会社 | 5-メチル-1-フェニル-2-(1h)-ピリドン含有貼付剤 |
US8287900B2 (en) | 2007-05-25 | 2012-10-16 | Lead Chemical Co., Ltd. | Medicated patch comprising 5-methyl-1-phenyl-2-(1H)-pyridone |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
JP2015509941A (ja) * | 2012-02-16 | 2015-04-02 | テバ ファーマシューティカル インダストリーズ リミティド | N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用 |
JP2016020369A (ja) * | 2009-04-01 | 2016-02-04 | ノヴィファーマ ソシエテ アノニム | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
WO2018139626A1 (ja) | 2017-01-30 | 2018-08-02 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
US10071085B2 (en) | 2009-04-01 | 2018-09-11 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2019098259A1 (ja) | 2017-11-17 | 2019-05-23 | 塩野義製薬株式会社 | 光安定性および溶出性に優れた医薬製剤 |
JP2019513145A (ja) * | 2016-03-29 | 2019-05-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 5−メチル−1−フェニル−2−(1h)−ピリドンの顆粒製剤及びその製造方法 |
CN110430871A (zh) * | 2017-03-02 | 2019-11-08 | 永进药品工业株式会社 | 可压缩性改善的粒度受控的吡非尼酮的药物组合物及其制备方法 |
US12129247B2 (en) | 2018-08-28 | 2024-10-29 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060446A1 (en) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
BRPI0413881A (pt) * | 2003-08-28 | 2006-10-24 | Sandoz Ag | composição farmacêutica compreendendo anticonvulsivante com revestimento de mascaramento de gosto |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
DK2124945T3 (da) * | 2006-12-18 | 2011-08-01 | Intermune Inc | Fremgangsmåde til at give pirfenidonterapi til en patient |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
CN101972236A (zh) * | 2010-10-13 | 2011-02-16 | 北京诚创康韵医药科技有限公司 | 一种含吡非尼酮的缓释制剂 |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
MX2011007675A (es) * | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
KR101453688B1 (ko) * | 2013-11-05 | 2014-11-04 | 포항공과대학교 산학협력단 | 광 입사 각도 선택성을 가지는 전자 소자 및 그 제조 방법 |
AU2015204558B2 (en) | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
TWI745396B (zh) | 2016-07-12 | 2021-11-11 | 日商鹽野義製藥股份有限公司 | 吸入用醫藥組成物 |
MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
CN109223723B (zh) * | 2017-07-11 | 2021-08-27 | 南京华威医药科技集团有限公司 | 吡非尼酮片剂及其制备方法和用途 |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
EP3511001B1 (en) | 2018-01-12 | 2021-09-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pirfenidone-containing tablet and capsule formulation |
CN115666533B (zh) * | 2020-04-22 | 2024-08-09 | 永进药品工业株式会社 | 具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法 |
AU2022443590A1 (en) | 2022-02-28 | 2024-10-17 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP0383591A2 (en) * | 1989-02-15 | 1990-08-22 | Yamauchi, Shitotomo | Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions |
WO1994026249A1 (en) * | 1993-05-07 | 1994-11-24 | Margolin Solomon B | Compositions and methods for reparation and prevention of fibrotic lesions |
WO1997010712A1 (en) * | 1995-09-19 | 1997-03-27 | Margolin Solomon B | Inhibition of tumor necrosis factor alpha |
US5681382A (en) * | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
WO1997041830A1 (en) * | 1996-05-09 | 1997-11-13 | Margolin Solomon B | Reparation and prevention of fibrotic lesions |
EP0901787A1 (en) * | 1997-09-10 | 1999-03-17 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US5271946A (en) * | 1988-04-20 | 1993-12-21 | Asta Pharma Aktiengesellschaft | Controlled release azelastine-containing pharmaceutical compositions |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
CA2164344C (en) * | 1993-08-30 | 2004-06-29 | Stanley Lech | Tablet coating based on a melt-spun mixture of a saccharide and a polymer |
US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
US5639754A (en) | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
MX9702531A (es) | 1994-10-07 | 1997-06-28 | Fujisawa Pharmaceutical Co | Compuesto nuevo. |
US6090822A (en) | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
CA2225250C (en) | 1995-06-21 | 2005-03-22 | Shionogi & Co., Ltd. | Bicyclic amino derivatives and pgd2 antagonist containing the same |
JPH091787A (ja) * | 1995-06-22 | 1997-01-07 | Canon Inc | 印字装置 |
US5962478A (en) | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
US6328994B1 (en) * | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
NZ521241A (en) | 2000-03-07 | 2004-02-27 | Ranbaxy Lab Ltd | Azole compounds as therapeutic agents for fungal infections |
US20030104066A1 (en) | 2000-03-27 | 2003-06-05 | Kouji Murai | Easy-to-take granules |
KR20030024799A (ko) | 2000-07-20 | 2003-03-26 | 뉴로젠 코포레이션 | 캡사이신 수용체 리간드 |
CA2423329A1 (en) | 2000-09-22 | 2003-03-20 | Takeda Chemical Industries, Ltd. | Solid preparations |
WO2002060446A1 (en) * | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
WO2002083134A1 (en) | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
JP4280074B2 (ja) | 2001-04-25 | 2009-06-17 | 大正製薬株式会社 | マルチプルユニット型徐放性錠剤 |
CA2468015A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 2-aminoquinoline compounds |
DK1472225T3 (da) | 2002-02-01 | 2010-08-09 | Euro Celtique Sa | 2-Piperazinpyridiner, som er anvendelige til behandling af smerte |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
AU2003247829A1 (en) | 2002-06-28 | 2004-01-19 | Euro-Celtique, S.A. | Therapeutic piperazine derivatives useful for treating pain |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
AU2003262811A1 (en) | 2002-08-27 | 2004-03-19 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
US20060110358A1 (en) | 2002-08-28 | 2006-05-25 | Hsu Henry H | Combination therapy for treatment of fibrotic disorders |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
WO2004035549A1 (en) | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
RS20050714A (sr) | 2003-03-31 | 2008-04-04 | Pliva-Lachema A.S., | Farmaceutski preparati koji kao aktivnu suptancu sadrže kompleks platine i postupci za njihovo dobijanje |
US20050008691A1 (en) | 2003-05-14 | 2005-01-13 | Arturo Siles Ortega | Bicalutamide compositions |
WO2004103296A2 (en) | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
US20070172446A1 (en) | 2003-05-16 | 2007-07-26 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
AR044688A1 (es) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
CA2531116A1 (en) | 2003-07-01 | 2005-01-20 | Michael Hawley | Diffusion layer modulated solids |
JP4521777B2 (ja) | 2003-07-24 | 2010-08-11 | ユーロ−セルティーク エス.エイ. | 疼痛治療または予防に有用な4−ヘテロアリール−テトラヒドロピペリジル化合物 |
CN1829708A (zh) | 2003-07-24 | 2006-09-06 | 尤罗塞尔蒂克股份有限公司 | 哌啶化合物和含有它们的药物组合物 |
JP5148110B2 (ja) | 2003-08-01 | 2013-02-20 | ユーロ−セルティーク エス.エイ. | 疼痛の治療に有用な治療薬 |
EP1664041B1 (en) | 2003-09-22 | 2008-07-02 | Euro-Celtique S.A. | Phenyl-carboxamide compounds useful for treating pain |
DE602004017481D1 (de) | 2003-09-22 | 2008-12-11 | Euro Celtique Sa | Zur behandlung von schmerzen geeignete therapeutische mittel |
US7407973B2 (en) | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
CA2545813C (en) | 2003-11-14 | 2011-01-04 | Shanghai Genomics, Inc. | The derivatives of pyridone and use thereof |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
DK1727801T3 (da) | 2003-12-30 | 2009-05-11 | Euro Celtique Sa | Til behandling af smerter anvendelige piperaziner |
SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
US8642079B2 (en) | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
EP1757591A4 (en) | 2004-05-26 | 2010-05-05 | Eisai R&D Man Co Ltd | ZIMTSÄUREAMIDVERBINDUNG |
CN102816170A (zh) | 2005-07-25 | 2012-12-12 | 因特蒙公司 | C型肝炎病毒复制的新颖大环抑制剂 |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US20090163549A1 (en) | 2005-12-15 | 2009-06-25 | Hiroyuki Kai | Pharmaceutical Composition Comprising an Amide Derivative |
PT2142529E (pt) | 2007-04-27 | 2014-03-20 | Purdue Pharma Lp | Antagonistas de trpv1 e as respectivas utilizações |
NZ579820A (en) | 2007-04-27 | 2011-01-28 | Purdue Pharma Lp | Therapeutic agents useful for treating pain |
EP2276734A1 (en) | 2008-04-17 | 2011-01-26 | Pfizer Inc. | 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
PE20140572A1 (es) | 2008-06-05 | 2014-05-16 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
US8546388B2 (en) | 2008-10-24 | 2013-10-01 | Purdue Pharma L.P. | Heterocyclic TRPV1 receptor ligands |
EP2585446A4 (en) | 2010-06-22 | 2013-12-25 | Shionogi & Co | COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE |
-
2002
- 2002-01-25 WO PCT/JP2002/000544 patent/WO2002060446A1/ja active Application Filing
- 2002-01-25 KR KR1020077018953A patent/KR100891887B1/ko active IP Right Grant
- 2002-01-25 AT AT02710352T patent/ATE452637T1/de not_active IP Right Cessation
- 2002-01-25 DE DE60234812T patent/DE60234812D1/de not_active Expired - Lifetime
- 2002-01-25 EP EP02710352A patent/EP1356816B1/en not_active Expired - Lifetime
- 2002-01-25 JP JP2002560638A patent/JP4077320B2/ja not_active Expired - Fee Related
- 2002-01-25 US US10/470,334 patent/US7867516B2/en not_active Expired - Lifetime
- 2002-01-25 KR KR1020037009856A patent/KR100777169B1/ko active IP Right Grant
- 2002-01-29 TW TW091101440A patent/TWI314868B/zh not_active IP Right Cessation
-
2010
- 2010-11-08 US US12/941,994 patent/US20110104276A1/en not_active Abandoned
-
2011
- 2011-12-21 US US13/333,142 patent/US20120183615A1/en not_active Abandoned
-
2012
- 2012-10-26 US US13/662,221 patent/US9017722B2/en not_active Expired - Fee Related
-
2015
- 2015-03-27 US US14/671,251 patent/US20150209341A1/en not_active Abandoned
- 2015-11-24 US US14/951,313 patent/US9561217B2/en not_active Expired - Lifetime
-
2016
- 2016-12-20 US US15/385,451 patent/US20170100380A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3974281A (en) * | 1972-12-18 | 1976-08-10 | Affiliated Medical Research, Inc. | 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use |
EP0383591A2 (en) * | 1989-02-15 | 1990-08-22 | Yamauchi, Shitotomo | Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention and treatment of fibrotic lesions |
WO1994026249A1 (en) * | 1993-05-07 | 1994-11-24 | Margolin Solomon B | Compositions and methods for reparation and prevention of fibrotic lesions |
US5681382A (en) * | 1995-08-22 | 1997-10-28 | Shin-Etsu Chemical Co., Ltd. | Rapidly soluble coating composition and method for preparing same |
WO1997010712A1 (en) * | 1995-09-19 | 1997-03-27 | Margolin Solomon B | Inhibition of tumor necrosis factor alpha |
WO1997041830A1 (en) * | 1996-05-09 | 1997-11-13 | Margolin Solomon B | Reparation and prevention of fibrotic lesions |
EP0901787A1 (en) * | 1997-09-10 | 1999-03-17 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005187339A (ja) * | 2003-12-24 | 2005-07-14 | Iwaki Seiyaku Co Ltd | 耐光性塩酸テルビナフィンフィルムコート錠 |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US8287900B2 (en) | 2007-05-25 | 2012-10-16 | Lead Chemical Co., Ltd. | Medicated patch comprising 5-methyl-1-phenyl-2-(1H)-pyridone |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8568770B2 (en) | 2008-11-21 | 2013-10-29 | Lead Chemical Co., Ltd. | Adhesive material containing 5-methyl-1-phenyl-2-(1H)-pyridone |
KR20110095385A (ko) | 2008-11-21 | 2011-08-24 | 리도 케미칼 가부시키가이샤 | 5-메틸-1-페닐-2-(1h)-피리돈 함유 첩부제 |
WO2010058844A1 (ja) | 2008-11-21 | 2010-05-27 | リードケミカル株式会社 | 5-メチル-1-フェニル-2-(1h)-ピリドン含有貼付剤 |
JP2016020369A (ja) * | 2009-04-01 | 2016-02-04 | ノヴィファーマ ソシエテ アノニム | ニトロカテコール誘導体を含む医薬製剤及びその製造方法 |
US10583130B2 (en) | 2009-04-01 | 2020-03-10 | Bial-Portela & Ca, S.A. | Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof |
US10071085B2 (en) | 2009-04-01 | 2018-09-11 | Bial—Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
JP2015509941A (ja) * | 2012-02-16 | 2015-04-02 | テバ ファーマシューティカル インダストリーズ リミティド | N−エチル−n−フェニル−1,2−ジヒドロ−4,5−ジ−ヒドロキシ−1−メチル−2−オキソ−3−キノリンカルボキサミド、その製剤、および使用 |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
JP2019513145A (ja) * | 2016-03-29 | 2019-05-23 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 5−メチル−1−フェニル−2−(1h)−ピリドンの顆粒製剤及びその製造方法 |
JP7456721B2 (ja) | 2016-03-29 | 2024-03-27 | エフ. ホフマン-ラ ロシュ アーゲー | 5-メチル-1-フェニル-2-(1h)-ピリドンの顆粒製剤及びその製造方法 |
US10953016B2 (en) | 2017-01-30 | 2021-03-23 | Shionogi & Co., Ltd. | Solid dosage form containing quinazoline derivative |
KR20190108606A (ko) | 2017-01-30 | 2019-09-24 | 시오노기세이야쿠가부시키가이샤 | 퀴나졸린 유도체를 함유하는 고형 제제 |
WO2018139626A1 (ja) | 2017-01-30 | 2018-08-02 | 塩野義製薬株式会社 | キナゾリン誘導体を含有する固形製剤 |
JP2020509053A (ja) * | 2017-03-02 | 2020-03-26 | ユンジン ファーム.カンパニー、リミテッド | ピルフェニドンの粒子の大きさ調節による打錠性が改善された薬剤学的組成物およびその製造方法 |
JP2022031527A (ja) * | 2017-03-02 | 2022-02-18 | ユンジン ファーム.カンパニー、リミテッド | ピルフェニドンの粒子の大きさ調節による打錠性が改善された薬剤学的組成物およびその製造方法 |
CN110430871A (zh) * | 2017-03-02 | 2019-11-08 | 永进药品工业株式会社 | 可压缩性改善的粒度受控的吡非尼酮的药物组合物及其制备方法 |
KR20200089290A (ko) | 2017-11-17 | 2020-07-24 | 시오노기세야쿠 가부시키가이샤 | 광안정성 및 용출성이 우수한 의약 제제 |
WO2019098259A1 (ja) | 2017-11-17 | 2019-05-23 | 塩野義製薬株式会社 | 光安定性および溶出性に優れた医薬製剤 |
US12064438B2 (en) | 2017-11-17 | 2024-08-20 | Shionogi & Co., Ltd. | Pharmaceutical preparation excellent in light stability and dissolution property |
US12129247B2 (en) | 2018-08-28 | 2024-10-29 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
Also Published As
Publication number | Publication date |
---|---|
EP1356816A4 (en) | 2005-02-09 |
US20160074375A1 (en) | 2016-03-17 |
TWI314868B (en) | 2009-09-21 |
JPWO2002060446A1 (ja) | 2004-05-27 |
US20120183615A1 (en) | 2012-07-19 |
KR100891887B1 (ko) | 2009-04-03 |
US20170100380A1 (en) | 2017-04-13 |
JP4077320B2 (ja) | 2008-04-16 |
US20130115288A1 (en) | 2013-05-09 |
EP1356816A1 (en) | 2003-10-29 |
KR100777169B1 (ko) | 2007-11-16 |
ATE452637T1 (de) | 2010-01-15 |
KR20030072608A (ko) | 2003-09-15 |
DE60234812D1 (de) | 2010-02-04 |
EP1356816B1 (en) | 2009-12-23 |
US7867516B2 (en) | 2011-01-11 |
US9017722B2 (en) | 2015-04-28 |
US9561217B2 (en) | 2017-02-07 |
KR20070093006A (ko) | 2007-09-14 |
US20040048902A1 (en) | 2004-03-11 |
US20150209341A1 (en) | 2015-07-30 |
US20110104276A1 (en) | 2011-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002060446A1 (en) | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
EP1027037B1 (en) | Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient | |
JP2007191419A (ja) | ピモベンダン経口投与製剤 | |
JP4567640B2 (ja) | 小型化塩酸サルポグレラート経口投与製剤 | |
JP2008214334A (ja) | 被覆された薬物含有粒子および該粒子を含む固形製剤 | |
JP2010120959A (ja) | 小型化塩酸サルポグレラート経口投与製剤 | |
JP2018177657A (ja) | レベチラセタム含有医薬組成物及びその製造方法 | |
JP6496084B2 (ja) | 口腔内崩壊錠 | |
KR101677775B1 (ko) | 붕괴성 및 용출성에 우수한 내복용 정제 | |
JP2015110663A (ja) | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 | |
WO2011081118A1 (ja) | 経口投与用医薬組成物 | |
JP4572293B2 (ja) | ピモベンダン経口投与製剤 | |
JP5282644B2 (ja) | 内服用錠剤 | |
JP2022537106A (ja) | メトホルミン及びクエン酸カルシウムを含む医薬剤形 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002560638 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002710352 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037009856 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10470334 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037009856 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2002710352 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |